12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onglyza saxagliptin regulatory update

The European Commission approved Onglyza saxagliptin from Bristol-Myers and AstraZeneca for use as a combination therapy with insulin, with or without metformin, to improve glycemic...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >